Compare WYNN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYNN | AXSM |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.2B |
| IPO Year | 2002 | 2015 |
| Metric | WYNN | AXSM |
|---|---|---|
| Price | $100.28 | $207.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $142.73 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 1.5M | 644.6K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $6,717,660,000.00 | N/A |
| Revenue This Year | $6.49 | $57.24 |
| Revenue Next Year | $4.58 | $55.88 |
| P/E Ratio | $42.20 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $92.52 | $112.90 |
| 52 Week High | $134.72 | $260.19 |
| Indicator | WYNN | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 38.34 |
| Support Level | $96.48 | $206.94 |
| Resistance Level | $100.59 | $236.26 |
| Average True Range (ATR) | 2.81 | 7.27 |
| MACD | -0.19 | -0.06 |
| Stochastic Oscillator | 28.23 | 15.60 |
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.